How many mg per click does a Wegovy pen deliver?

Why each pen has exactly one dose value, and nothing in between

The Wegovy auto-injector pen is designed around simplicity and accuracy. Press the button once against the injection site, hold for six seconds, and the full pre-filled dose is delivered. There is no plunger to push partially, no graduation marks, and no mechanism for a half-dose. What you get is what the pen contains for that single injection, which is why our guide to the Wegovy 1mg dose per click explains that asking about dose per click is essentially another way of asking which pen strength you are holding.

This design is deliberate. Subcutaneous GLP-1 medicines need consistent dosing week to week; variability would undermine both the pharmacology and the safety data on which the licence is based. The full dose chart maps every licensed UK strength against what each click delivers, which is a straightforward one-to-one relationship.

A question our prescribers hear most weeks is whether you can "take a smaller click" when side effects feel rough, and if you want a fuller explanation of how the click dose on Wegovy works, that page covers the mechanism in plain terms. Staying at the current pen strength for longer before moving up is a clinically recognised approach, and it is exactly the kind of decision that belongs in a prescriber review rather than a self-adjustment.

Reading the 2.4 mg maintenance pen: what the clinical evidence says about dose and outcome

The pivotal STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide 2.4 mg weekly over 68 weeks alongside lifestyle intervention. Participants reached an average body-weight reduction of around 15%. That figure is attached to the full maintenance dose (the 2.4 mg pen) reached after a titration sequence that begins at 0.25 mg.

The 0.25 mg starting pen is not a therapeutic dose in the sense of driving substantial weight loss; its role is to let the body adjust to the medicine before the dose climbs. The 0.25 mg pen delivers 0.25 mg per click, and for most people it is used for the first four weeks only. Moving through 0.5 mg and 1.0 mg follows at roughly four-week intervals, again as directed by the prescriber. Reaching 2.4 mg typically takes about sixteen weeks.

The NHS's medicines guidance for semaglutide describes this titration clearly and is worth reading alongside any prescriber conversation. Understanding that the dose-per-click climbs in steps (not in a single jump) helps set realistic expectations about when results become noticeable.

The 7.2 mg pen: what the April 2026 approval added

On 14 April 2026 the MHRA approved a dedicated higher-strength single-dose pen delivering 7.2 mg of semaglutide per click, the maximum dose in the updated schedule. This pen has a built-in covered needle and locks after use. It is licensed for adults with a BMI of 30 or above and is reached after titrating through the earlier strengths; the MHRA's approval announcement confirms it is not indicated for BMI below 30 or for the cardiovascular risk-reduction licence.

Trial data at 7.2 mg reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide at its highest dose. Whether 7.2 mg is appropriate for a given patient is a clinical judgement, not every patient needs or tolerates the highest available strength, and some do very well at 2.4 mg.

If you are weighing up which GLP-1 option fits your situation, the treatment overview sets out the licensed choices available through nume. Semaglutide's mechanism (a single GLP-1 receptor pathway) differs from tirzepatide's dual GIP and GLP-1 action, and prescribers consider both the clinical profile and the patient's history when making a recommendation.

Storage, injection technique, and not adjusting doses yourself

Each pen should be stored in the fridge between 2°C and 8°C until first use. Room-temperature storage is permitted for a limited window, the Patient Information Leaflet gives the exact duration and that is the document to follow, not a general estimate. The injection sites are the abdomen, outer thigh, or upper arm; rotating sites from week to week reduces localised reactions.

Side effects are most common at the start of treatment or after moving to a higher-strength pen. The typical pattern is gastrointestinal: nausea, loose stools, constipation, or reflux, usually settling over days to a couple of weeks. Most people find these manageable with small meal portions, steady hydration, and avoiding rich or fatty food during the adjustment period. Severe, persistent stomach pain (particularly if it radiates toward the back) needs prompt medical assessment; the MHRA has specifically highlighted acute pancreatitis as a known risk with GLP-1 medicines and issued formal guidance on this in January 2026.

Missed doses, switching pen strengths, or adjusting the timing of injections should always go through a prescriber. If you would like a clinical assessment to find out whether Wegovy could be appropriate for you, check your eligibility with our prescribers, consultations are free, reviewed the same day, and carry no obligation.